Ozempic Enters India: Diabetes Drug, Not a 'Miracle Fix', Novo Nordisk MD To NDTV

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment in the country, where more than 100 million adults live with type 2 diabetes. While the drug has drawn global attention for its weight loss effects and celebrity use, the company says its India rollout is focused squarely on diabetes care, scientific evidence, and responsible medical use.